HAE - CIK 0000313143
HAEMONETICS CORP (HAE) reported revenue of $1.33B for fiscal year 2026, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2026 | $1.33B | -2.0% |
| FY 2025 | $1.36B | +4.0% |
| FY 2024 | $1.31B | +12.0% |
| FY 2023 | $1.17B | +17.7% |
| FY 2022 | $993.20M | +14.1% |
| FY 2021 | $870.46M | -11.9% |
| FY 2020 | $988.48M | +2.2% |
| FY 2019 | $967.58M | +7.0% |
| FY 2018 |
HAEMONETICS CORP (HAE) reported revenue of $1.33B for fiscal year 2026, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2026, HAEMONETICS CORP's revenue grew from $676.69M to $1.33B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $903.92M |
| +2.0% |
| FY 2017 | $886.12M | -2.7% |
| FY 2015 | $910.37M | -3.0% |
| FY 2014 | $938.51M | +5.2% |
| FY 2013 | $891.99M | +22.6% |
| FY 2012 | $727.84M | +7.6% |
| FY 2011 | $676.69M | - |